Uttara Paingankar

SiNON Therapeutics patented Carbon NanoDots (CNDsTM) are a drug delivery system with a novel release mechanism that allows for targeted treatment for brain tumors and other neurological diseases. At SiNON Therapeutics we have developed a tunable, platform delivery system that is engineered to encapsulate multiple different therapeutics, including biologics, up to 500kD, and deliver them across the blood-brain barrier (BBB) to treat neurological diseases. Because our CNDs will open only at the site of the tumor and not at healthy tissues, we can deliver higher doses with less overall toxicity for increased therapeutic efficacy. It has been shown that 30-40% of cancers metastasize to the brain yet due to the fact that only 2% of therapies can cross the BBB, the survival rate for patients with brain cancers is only 34%. Our mission is to give hope to thousands of patients suffering from brain tumors that presently have few options for life-saving treatments.

Fidelity’s mission is to strengthen the financial well-being of our customers and deliver better outcomes for the clients and businesses we serve. Fidelity’s strength comes from the scale of our diversified, market-leading financial services businesses that serve individuals, families, employers, wealth management firms, and institutions. With assets under administration of $15.0 trillion, including discretionary assets of $5.9 trillion as of March 31, 2025, we focus on meeting the unique needs of a broad and growing customer base. Privately held for 78 years, Fidelity employs more than 77,000 associates across the United States, Ireland, and India. For our Terms and Conditions, please visit http://go.fidelity.com/LIterms

SiNON Therapeutics patented Carbon NanoDots (CNDsTM) are a drug delivery system with a novel release mechanism that allows for targeted treatment for brain tumors and other neurological diseases. At SiNON Therapeutics we have developed a tunable, platform delivery system that is engineered to encapsulate multiple different therapeutics, including biologics, up to 500kD, and deliver them across the blood-brain barrier (BBB) to treat neurological diseases. Because our CNDs will open only at the site of the tumor and not at healthy tissues, we can deliver higher doses with less overall toxicity for increased therapeutic efficacy. It has been shown that 30-40% of cancers metastasize to the brain yet due to the fact that only 2% of therapies can cross the BBB, the survival rate for patients with brain cancers is only 34%. Our mission is to give hope to thousands of patients suffering from brain tumors that presently have few options for life-saving treatments.